Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer - PubMed

4 hours ago

Pathologic complete response (pCR) after neoadjuvant treatment (NAT) is prognostic for recurrence-free survival (RFS) and overall survival (OS) in breast cancer (BC).
Study assessed prognostic factors for RFS and OS in patients with pCR compared to residual disease (RD) in HER2+ and triple-negative breast cancer (TNBC).
863 patients (median age 50.2) underwent surgery from 2016 to 2021, with a median follow-up of 3.5 years.
Three-year RFS was 87% overall, 93% in HER2+, and 80% in TNBC cohorts.
Among 374 pCR patients (43.3%), 3-year RFS was 98%, compared to 79% in 489 RD patients (56.7%).
In HER2+ BC, 3-year RFS was 99% for pCR vs. 87% for RD, while in TNBC it was 97% for pCR vs. 72% for RD.
Higher cT, positive cN, TNBC subtype, and RD were associated with poorer RFS and OS.
In pCR, 3-year RFS was numerically higher in cT1-2 compared to cT3-4 and in cN0 compared to cN+ (not significant).
In RD, higher cT, positive cN, and TNBC subtype remained associated with poorer outcomes.
Multivariate analysis found no associations in pCR patients.
Conclusion: Patients experiencing pCR had better outcomes. cT, cN, and subtype were prognostic only in patients with RD.

Hasty Briefsbeta